Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
Our projected 24% reduction in cardiovascular events in persons with overweight or obesity but without cardiovascular disease from tirzepatide compares favorably to the well-publicized SELECT trial published last year involving another weight-loss medication Wegovy (semaglutide 2.4 milligram), which was studied in persons with cardiovascular disease and showed a 20% reduction in future cardiovascular events, said Wong, who also previously published a similar analysis of semaglutide estimating an 18% risk reduction in persons without cardiovascular disease
The WHO December 2025 guideline and what it means for BMI thresholds In December 2025, the World Health Organization released its first-ever guideline on the use of GLP-1 therapies for treating obesity in adults
While these medications deliver impressive weight loss results, theyve created an unexpected challenge: managing excess skin after rapid weight reduction
Shi Q, Nong K, Vandvik PO et al (2023) Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials
Why are patients with non-alcoholic fatty liver disease (NAFLD) suddenly being
Quando nos alimentamos, o intestino libera GLP-1 na corrente sangunea
